Rivastigmine

Description

Rivastigmine is used to treat mild-to-moderate dementia associated with Alzheimer's disease and Parkinson's disease. This medicine does not cure Parkinson's or Alzheimer's but it may slow the loss of or improve the patient's awareness of surroundings, ability to perform daily functions, and ability to think and remember.

Side effects

Major & minor side effects for Rivastigmine

  • Decreased appetite
  • Urinary tract infection
  • Nausea and Vomiting
  • Seizures
  • Diarrhea
  • Weight loss
  • Heartburn
  • Stomach pain
  • Dizziness
  • Urinary retention/incontinence
  • Skin Reactions

Uses of Rivastigmine

What is it prescribed for?

  • Dementia
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The effect of this medicine lasts for an average duration of 10 to 12 hours after oral administration and 24 hours after a transdermal patch is applied.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit forming tendency has been reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. Discuss all the risks and benefits with your doctor before using this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the medicine or to discontinue breastfeeding based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to rivastigmine, other cholinesterase inhibitors, or any other inactive ingredients present along with this medicine.

Transdermal patch site reactions

This medicine is not recommended for use in patients with a history of application site reactions suggestive of allergic contact dermatitis with a rivastigmine transdermal patch.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. Discuss all the risks and benefits with your doctor before using this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the medicine or to discontinue breastfeeding based on your clinical condition.
General warnings

Driving vehicles and operating machinery

This medicine should be used with extreme caution due to the increased risk of side effects such as dizziness, fainting, and drowsiness. It is advised that you do not perform any activities that require high mental alertness such as driving a vehicle or operating machinery during treatment with this medicine.

Gastrointestinal bleeding

This medicine should be used with caution due to an increase in the risk of gastrointestinal bleeding. This risk is especially higher in patients with a history of gastrointestinal disorders. Report any unusual symptoms such as blood in the stool, heartburn, etc. to the doctor immediately. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Patients with low body weight

This medicine should be used with extreme caution in patients with low body weight (less than 50 kg) due to the increased risk of severe adverse effects. Appropriate dose adjustments may be necessary based on the clinical condition of the patient.

Skin application site reactions

This medicine may cause skin application site reactions in some patients. This may potentially lead to allergic contact dermatitis in some cases. Allergic contact dermatitis should be suspected if the reactions spread beyond the patch size or if symptoms do not improve within 48 hours after patch removal. In such cases, treatment should be discontinued. In patients who develop application site reactions with transdermal patch form of this medicine, treatment should be switched to oral form only after negative allergy testing and under close medical supervision.

Extrapyrimadal symptoms

This medicine may exacerbate or induce extrapyramidal symptoms such as tremors in some patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Missed Dose

Take/Apply the missed dose as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose. Do not take/apply a double dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor immediately in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Metoprolol

Quetiapine

Tramadol

Bupropion

Disease interactions

Bradycardia

This medicine is not recommended for use in patients with pre-existing bradycardia since it may worsen the patient's condition. Replacement with a suitable alternative should be considered under your doctor's supervision.

Peptic ulcer disease

This medicine should be used with extreme caution in patients with a known history of peptic ulcer disease since it may worsen the patient's condition. Report any unusual side effects to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Seizures

This medicine should be used with caution in patients with a known history of seizures since it may worsen the patients' condition. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Respiratory Disorders

This medicine should be used with caution in patients with a known history of respiratory disorders such as asthma, chronic obstructive pulmonary disease, etc. since it may worsen the patient's condition. Close monitoring of respiratory function, appropriate dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Food interactions
Information not available.
Lab interactions
Information not available.
Patch: Before you apply a patch, make sure that your skin is clean, dry and hairless, free of any powder, oil, moisturizer or lotion that could keep the patch from sticking to your skin properly, free of cuts, rashes or irritations. Capsule: Take this medicine with food. Do not use/take in larger amounts than advised or prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken with food

To be taken as instructed by doctor

May cause sleepiness

How it works
It works by restoring the balance of certain natural substances in the brain to improve the function of the nerve cells in the brain.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Cholinesterase inhibitors

Schedule

Schedule H

[Internet]. 2018 [cited 11 January 2018]. Available from:

https://www.medicines.org.uk/emc/product/8510

[Internet]. 2018 [cited 11 January 2018]. Available from:

https://www.medicines.org.uk/emc/files/pil.1185.pdf

DailyMed - Rivastigmine patch, extended release [Internet]. Dailymed.nlm.nih.gov. 2018 [cited 11 January 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92a58ebb-748d-49f4-bf11-ecbcf5424152

Rivastigmine: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2018 [cited 11 January 2018]. Available from:

https://medlineplus.gov/druginfo/meds/a602009.html

Rivastigmine - DrugBank [Internet]. Drugbank.ca. 2018 [cited 11 January 2018]. Available from:

https://www.drugbank.ca/drugs/DB00989

[Internet]. 2018 [cited 20 February 2018]. Available from:

https://www.medicines.org.uk/emc/product/2059/pil

[Internet]. 2018 [cited 20 February 2018]. Available from:

https://www.medicines.org.uk/emc/product/4835

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 20 Feb 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.